厄贝沙坦氢氯噻嗪片治疗原发性高血压的疗效及对血清TNF-α、IL-6水平的影响

Effect of irbesartan hydrochlorothiazide tablets on essential hypertension and serum TNF-α and IL-6 levels

目的 探讨厄贝沙坦氢氯噻嗪片治疗原发性高血压的临床疗效以及对患者血清肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）水平的影响。方法 将2014年7月~2016年9月期间在杭州市余杭区第五人民医院接受治疗的86例原发性高血压患者随机分成2组,对照组43例采用厄贝沙坦片治疗,实验组43例采用厄贝沙坦氢氯噻嗪片治疗,比较2组患者的临床疗效、血压及血清TNF-α、IL-6因子变化情况以及不良反应的发生情况。结果 实验组患者总有效率为93.02%,对照组患者总有效率为76.74%,实验组的总有效率显著高于对照组,差异有统计学意义（P〈0.05）。治疗前,2组患者的收缩压与舒张压差异无统计学意义;治疗8周后,2组患者的收缩压与舒张压均有所下降,且实验组患者的下降程度更为明显,2组之间差异具有统计学意义（P〈0.05）。治疗前,2组患者的血清TNF-α、IL-6因子差异无统计学意义;治疗8周后,2组患者的血清TNF-α、IL-6因子均有所下降,且实验组患者的下降程度更为明显,2组之间差异显著,具有统计学意义（P〈0.05）。43例实验组患者中出现头晕头痛1例,不良反应发生率为2.33%;43例对照组患者中脚踝水肿2例,头晕头痛3例,尿酸轻度增高2例,不良反应发生率为16.28%,实验组的不良反应发生率明显低于对照组,差异具有统计学意义（P〈0.05）。结论 采用厄贝沙坦氢氯噻嗪片治疗原发性高血压,临床疗效明显,患者血清TNF-α、IL-6因子下降明显,安全性高。

Objective To investigate the clinical efficacy of irbesartan hydrochloride and its effect on serum levels of tumor necrosis factor-α （TNF-α） and interleukin-6 （IL-6） in patients with essential hypertension. Methods From 86 patients with essential hypertension who were treated in our hospital from July 2014 to September 2016 were randomly divided into experimental group and control group. 43 patients in the control group were treated with irbesartan tablets. Group 43 patients were treated with irbesartan hydrochlorothiazide tablets, and the clinical efficacy, blood pressure and serum TNF-a, IL-6 factor and the incidence of adverse reactions were compared between the two groups. Results The effective rate was 93. 02% in experimental group the total effective rate control group was 76. 74 % ,the total effective rate of the experimental group was significantly higher than the control group, the difference was statistically significant （ P 〈 0. 05 ）. Before and after treatment, the systolic and diastolic blood pressure were higher in the experimental group and the control group, and there was no significant difference between the two groups. After eight weeks of treatment, Systolic and diastolic blood pressure were decreased, and the degree of decline in the experimental group was more obvious, the difference between the two groups was significant, statistically significant （ P 〈 0. 05 ） . There was no significant difference in serum TNF-a and IL-6 between the experimental group and the control group before treatment. After eight weeks of treatment, the serum TNF-a, IL-6 factor decreased, and the degree of decline in the experimental group was more obvious, the difference between the two groups was significant, statistically significant （ P 〈 0. 05 ）. The incidence of adverse reactions was 2. 33% in 43 patients, 43 cases of ankle edema in the control group, 3 cases of dizziness and headache, 2 cases of mild uric acid and two cases of adverse reaction. The incidence of adverse reactions was 16. 28% , The incidence of adverse reactions in the experimental group was significantly lower than the control group, the difference was statistically significant （ P 〈 0. 05 ）. Conclusion The treatment of essential hypertension with irbesartan hydrochloride is obvious, and the serum TNF-α and IL-6 are decreased and the safety is high.